Wei Ji1, Hong Xie1, Bojun Wei2, Hong Shen2, Aizhu Liu1, Ying Gao3, Lingling Wang3. 1. Department of Otorhinolaryngology Head and Neck Surgery, Beijing Shijitan Hospital, Capital Medical University Beijing, P. R. China. 2. Department of Thyroid and Neck Surgery, Beijing Chaoyang Hospital, Capital Medical University Beijing, P. R. China. 3. Department of Pathology, Beijing Shijitan Hospital, Capital Medical University Beijing, P. R. China.
Abstract
OBJECTIVE: This study aims to investigate the relationship between BRAF V600E gene mutation and the clinical and pathologic characteristics of patients with papillary thyroid microcarcinoma (PTMC). METHODS: A retrospective analysis was conducted on the clinical and pathologic characteristics of 89 patients with PTMC, who had complete medical records. The BRAF V600E gene mutation was detected by real-time immunofluorescence quantitative PCR. Then, the BRAF V600E gene mutation and the clinical and pathologic data of these patients were statistically analyzed. RESULTS: Among the 89 patients with PTMC, 67 patients had a BRAF V600E mutation with a mutation rate of 75.3%. 38 patients (42.6%) had cervical lymph node metastasis. 43 patients had capsular invasion (48.3%) and 40 patients (44.9%) had tumor multifocality confirmed by postoperative pathology. BRAF V600E mutation was not associated with gender, age, capsular invasion, tumor multifocality, cervical lymph node metastasis, or higher TNM stage. However, cervical lymph node metastasis was associated with age and tumor invasion of the capsule. Thus, cervical lymph node metastasis was most likely in patients < 45 years old and patients with capsular invasion. CONCLUSION: BRAF V600E mutation is common in PTMC, but is not associated with clinicopathologic factors, such as age, gender, tumor multifocality, cervical lymph node metastasis, capsular invasion, or tumor TNM stage. Cervical lymph node metastasis is more likely in patients < 45 years old and patients with capsular invasion. IJCEP
OBJECTIVE: This study aims to investigate the relationship between BRAFV600E gene mutation and the clinical and pathologic characteristics of patients with papillary thyroid microcarcinoma (PTMC). METHODS: A retrospective analysis was conducted on the clinical and pathologic characteristics of 89 patients with PTMC, who had complete medical records. The BRAFV600E gene mutation was detected by real-time immunofluorescence quantitative PCR. Then, the BRAFV600E gene mutation and the clinical and pathologic data of these patients were statistically analyzed. RESULTS: Among the 89 patients with PTMC, 67 patients had a BRAFV600E mutation with a mutation rate of 75.3%. 38 patients (42.6%) had cervical lymph node metastasis. 43 patients had capsular invasion (48.3%) and 40 patients (44.9%) had tumor multifocality confirmed by postoperative pathology. BRAFV600E mutation was not associated with gender, age, capsular invasion, tumor multifocality, cervical lymph node metastasis, or higher TNM stage. However, cervical lymph node metastasis was associated with age and tumor invasion of the capsule. Thus, cervical lymph node metastasis was most likely in patients < 45 years old and patients with capsular invasion. CONCLUSION:BRAFV600E mutation is common in PTMC, but is not associated with clinicopathologic factors, such as age, gender, tumor multifocality, cervical lymph node metastasis, capsular invasion, or tumor TNM stage. Cervical lymph node metastasis is more likely in patients < 45 years old and patients with capsular invasion. IJCEP